tacrolimus has been researched along with pazopanib* in 1 studies
1 other study(ies) available for tacrolimus and pazopanib
| Article | Year |
|---|---|
Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles.
Activation of pregnane X receptor (PXR) results in the induction of first-pass metabolism and drug efflux. Hereby, PXR may cause adverse drug reactions or therapeutic failure of drugs. PXR inhibition is thus an attractive option to minimise adverse effects or to improve therapeutic efficiencies; however, only a limited number of antagonists have been identified so far. We performed a cell-based high-throughput screen to identify PXR antagonists, using a library of approved and investigational drugs. Two approved drugs, pimecrolimus and pazopanib, emerged as novel potent antagonists of PXR activation, with IC Topics: Cell Line; Drug Approval; Hep G2 Cells; Hepatocytes; Humans; Indazoles; Molecular Docking Simulation; Pregnane X Receptor; Protein Binding; Pyrimidines; Sulfonamides; Tacrolimus | 2018 |